Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials? Mario P. ColomboMonica Rodolfo Review Pages: 265 - 270
High-dose continuous venous infusion of interleukin-2: Influence of dose and infusion rate on tumoricidal function and lymphocyte subsets Wilson C. MertensDiponkar BanerjeePeeyush K. Lala Original Article Pages: 271 - 279
A flow cytometric study of c-erbB-3 expression in breast cancer Ian BrotherickBrian K. ShentonThomas W. J. Lennard Original Article Pages: 280 - 286
Therapy with interleukin-2 induces the systemic release of phospholipase-A2 Gert Jan WolbinkCaspar SchalkwijkC. Erik Hack Original Article Pages: 287 - 292
Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumour cells does not affect tumour-specificity Wilhelmina M. C. MulderMarij J. StukartElisabeth Bloemena Original Article Pages: 293 - 301
Anti-(transforming growth factor β) antibodies with predefined specificity inhibit metastasis of highly tumorigenic human xenotransplants in nu/nu mice Magdalene HoeferF. Alfred Anderer Original Article Pages: 302 - 308
Antiproliferative effects of bacillus Calmette-Guérin and interferon α2b on human bladder cancer cells in vitro Kimberley PryorPhillip StrickerRonald Penny Original Article Pages: 309 - 316
Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon γ secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells Atsushi ArugaSuyu ShuAlfred E. Chang Original Article Pages: 317 - 324
